SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

BTC BTC Health Limited

Healthcare · Biotechnology · website
$0.06
52wk 0.05 – 0.07
Overall
58.4
Value
42.8
Growth
100.0
Health
69.2
Quality
24.8
Momentum
43.0
Dividend
—
Price
About BTC Health Limited

BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare, acute pain management, neuro-spinal, cardiovascular, pharmaceutical, medical technologies, biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia & New Zealand. The fund invests in both listed and unlisted companies.

Price analytics

Returns

1 day 0.0%
1 week -1.7%
1 month -5.0%
3 months -1.7%
6 months 3.6%
1 year -8.1%
3 years 39.0%

Risk

Volatility (1y ann.) 37.0%
Beta vs ASX 200 0.16
Sharpe (1y) -0.14
VaR 95% (1-day) -3.3%
Max drawdown (1y) -25.7%
Off 1-year high -18.6%

Technicals

RSI(14) 20 OS
vs 50DMA -3.3%
vs 200DMA -2.5%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 42.8
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
—
Price / Book
86
Price / Sales
0
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
100
EPS CAGR (3y)
—
Financial Health 69.2
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow) 24.8
Return on equity
2
Return on assets
0
Operating margin
0
Net margin
100
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 43.0
6-month return vs ASX 200
58
Price vs 200-day average
42
Price vs 50-day average
33
Position in 52-week range
32

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$20.37M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
-0.19
EV / EBITDA
—
Price / Book
1.84
ROE
0.3%
Operating margin
-565.6%
Net margin
118.0%
Total cash
$1.47M
Total debt
$0
Current ratio
8.38
Debt / Equity
—
Free cash flow
$-204,477
Avg volume
13,862
Latest annual results (FY ending 30 Jun 2026)
  • Revenue—
  • Gross profit—
  • Operating income-$422.83K
  • Net income$34.73K
  • Diluted EPS—
  • Free cash flow-$353.88K
  • Net debt-$1.47M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4